You are here: Industry Insights > lymphoma

News List

With the BGB-16673 Clinical Trials of BeiGene Launched, PROTAC Leads a Brand New Trend of Global Competition PharmaSources/Wanghong
March 21, 2022
On February 28, BGB-16673, a BTK-targeted PROTAC drug of BeiGene, was launched for clinical trials for the first time in China.
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023 PharmaSources
December 14, 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
Overall, Night Shift Work Not Tied to Higher Lymphoma Risk drugs.com
January 24, 2022
Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online...
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting prnasia
December 15, 2021
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics...
Press Release Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymph FirstWordPharma
December 13, 2021
Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile.
Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication Drugs
December 08, 2021
Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies...
Ledaga recommended by NICE for rare type of lymphoma pharmatimes
July 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that affects the skin.
FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial americanpharmaceuticalreview
July 14, 2021
AVM Biotechnology, a clinical-stage company, announced FDA permission to modify its ongoing non-Hodgkin's lymphoma/leukemia clinical study.
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines prnasia
May 06, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese ...
Viracta Announces Patent Application for Epstein-Barr Virus-Associated Lymphoma Treatment Candidate americanpharmaceuticalreview
February 19, 2021
Viracta Therapeutics announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082.

Previous page 1 2 3 4 5 Next page